India Pharma Exports Rise 5.6% to $28.29B, Eyes $130B by 2030
India Pharma Exports Rise 5.6% to $28.29B, Eyes $130B by 2030
Pharma exports rise 5.6% to $28.29B in FY26; the sector valued at $60B aims for $130B by 2030 despite US tariff risks.
India’s pharma exports rose 5.6% to $28.29 billion in April–February FY26, continuing a robust run for a sector now valued around $60 billion. Strong demand in key markets and steady domestic production have helped offset global headwinds, with leaders optimistic about a longer growth trajectory.
A key highlight is the projected leap to $130 billion in exports by 2030, underscoring ambitions to deepen manufacturing, diversify product lines, and expand into new markets. However, industry insiders acknowledge the challenge of possible US tariff measures on future shipments and stress the need for resilient supply chains, including greater domestic sourcing of raw materials.
Fiscal and policy support, along with ongoing investments in R&D and manufacturing capacity, could keep India on track to hit the ambitious target. The current growth also bodes well for jobs, regional development, and the broader push to position India as a global pharma hub despite intermittent volatility in global trade.
With pharma exports showing steady momentum into FY26, stakeholders remain cautiously optimistic as the sector navigates tariff talks and global market shifts while pursuing deeper global reach.
